ICON plc
(NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of
iSite
, a secure web-based portal that drives efficiency by providing investigators 24-hour access to study-specific laboratory information from
ICON Central Laboratories
.
iSite
is an easy-to-use portal that allows investigators and other site personnel to access electronic laboratory reports for their active studies at any time. It includes user-friendly navigation, filtering and report management and provides investigators customised views of reports by study, site, subject or visit date. iSite also includes email alert functionality which notifies investigators when new reports become available.
“We are continuously looking to introduce innovative technology solutions that drive efficiency and improve performance,” commented
Tom O’Leary
, President, ICON Central Laboratories. “iSite provides investigators a much needed solution for accessing important study-specific information in the most rapid, secure and convenient way possible.”
A future release of iSite is in development and will provide sites with study-specific performance metrics and additional tools such as customised electronic laboratory manuals which will be created by ICON’s
Firecrest™ technology
. ICON’s Firecrest delivers an innovative suite of training and study management tools which can significantly improve the compliance, consistency and execution of study-related activities at investigator sites.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.